Terms: = Lung cancer AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406
328 results:
1. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract] [Full Text] [Related]
3. Low Exposures to Amphibole or Serpentine Asbestos in Germline bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment.
Kadariya Y; Sementino E; Ruan M; Cheung M; Hadikhani P; Osmanbeyoglu HU; Klein-Szanto AJ; Cai K; Testa JR
Cancer Res Commun; 2024 Apr; 4(4):1004-1015. PubMed ID: 38592450
[TBL] [Abstract] [Full Text] [Related]
4. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract] [Full Text] [Related]
5. Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure.
Tuncel T; Ak G; Güneş HV; Metintaş M
J Environ Pathol Toxicol Oncol; 2024; 43(2):13-27. PubMed ID: 38505910
[TBL] [Abstract] [Full Text] [Related]
6. Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
Rigon M; Mutti L; Campanella M
Mol Oncol; 2024 Apr; 18(4):797-814. PubMed ID: 38459714
[TBL] [Abstract] [Full Text] [Related]
7. bap1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract] [Full Text] [Related]
8. Mesothelioma of Uncertain Malignant Potential (MUMP) of the Tunica Vaginalis: Proposal for Reclassification as "Complex Mesothelial Tumor of the Tunica Vaginalis".
Ding CC; Van Roo J; Kryvenko ON; Ye H; McKenney JK; Epstein JI
Am J Surg Pathol; 2024 Apr; 48(4):387-394. PubMed ID: 38270560
[TBL] [Abstract] [Full Text] [Related]
9. Investigation of MTAP and bap1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
[TBL] [Abstract] [Full Text] [Related]
10. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract] [Full Text] [Related]
11. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a bap1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract] [Full Text] [Related]
12. Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell lung cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.
Passiglia F; Righi L; Bironzo P; Listì A; Farinea G; Capelletto E; Novello S; Merlini A; Scagliotti GV
Clin Cancer Res; 2024 Mar; 30(5):959-964. PubMed ID: 38109438
[TBL] [Abstract] [Full Text] [Related]
13. Methylthioadenosine Phosphorylase and Breast cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y
Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371
[TBL] [Abstract] [Full Text] [Related]
14. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
[TBL] [Abstract] [Full Text] [Related]
15. Combined Inhibition of EZH2 and FGFR is Synergistic in bap1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
Nash A; Creaney J
Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
[TBL] [Abstract] [Full Text] [Related]
17. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with bap1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract] [Full Text] [Related]
18. Updates in Management of Malignant Pleural Mesothelioma.
John A; O'Sullivan H; Popat S
Curr Treat Options Oncol; 2023 Dec; 24(12):1758-1789. PubMed ID: 37975977
[TBL] [Abstract] [Full Text] [Related]
19. Contribution of bap1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract] [Full Text] [Related]
20. Preventive and therapeutic opportunities: targeting bap1 and/or HMGB1 pathways to diminish the burden of mesothelioma.
Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H
J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686
[TBL] [Abstract] [Full Text] [Related]
[Next]
